• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

作者信息

Adhoute Xavier, Castellani Paul, Bourlière Marc

机构信息

Department of Hepato-Gastroenterology, Hôpital Saint-Joseph, Marseille, France.

出版信息

Transl Gastroenterol Hepatol. 2017 Dec 18;2:110. doi: 10.21037/tgh.2017.12.04. eCollection 2017.

DOI:10.21037/tgh.2017.12.04
PMID:29354767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5762991/
Abstract
摘要

相似文献

1
Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.直接作用抗病毒药物对肝细胞癌风险的影响。
Transl Gastroenterol Hepatol. 2017 Dec 18;2:110. doi: 10.21037/tgh.2017.12.04. eCollection 2017.
2
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
3
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
4
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
5
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌：一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
6
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.直接作用抗病毒药物对肝细胞癌复发影响的证据不足：来自三个法国国家研究署队列的数据。
J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.
7
Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.直接作用抗病毒药物的无干扰素慢性丙型肝炎治疗不会改变肝硬化患者新发肝细胞癌的短期风险。
Aliment Pharmacol Ther. 2018 Feb;47(4):516-525. doi: 10.1111/apt.14427. Epub 2017 Dec 4.
8
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.直接作用抗病毒药物对 HCV 相关 HCC 早期复发的影响：与基于干扰素的治疗比较。
J Hepatol. 2019 Jan;70(1):78-86. doi: 10.1016/j.jhep.2018.09.029. Epub 2018 Oct 16.
9
Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?慢性丙型肝炎病毒感染直接抗病毒治疗后发生肝细胞癌：这是一种实际风险吗？
IDCases. 2018 Aug 30;14:e00450. doi: 10.1016/j.idcr.2018.e00450. eCollection 2018.
10
[Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].[丙型肝炎相关肝细胞癌与直接抗病毒药物治疗]
Zhonghua Gan Zang Bing Za Zhi. 2017 Dec 20;25(12):944-947. doi: 10.3760/cma.j.issn.1007-3418.2017.12.013.

引用本文的文献

1
A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience.β地中海贫血患者肝细胞癌（HCC）的发病率、主要危险因素及监测：过去、现在和未来展望以及ICET-A经验的简要综述
Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020006. doi: 10.4084/MJHID.2020.006. eCollection 2020.
2
No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis.直接作用抗病毒治疗后肝细胞癌发生率更高的证据不足：一项荟萃分析。
Hepatoma Res. 2019;5. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.
3
Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions.扩大肝移植米兰标准在肝癌治疗中的应用：未来的方向。
World J Gastroenterol. 2018 Aug 28;24(32):3626-3636. doi: 10.3748/wjg.v24.i32.3626.

本文引用的文献

1
Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.直接作用抗病毒药物治疗丙型肝炎病毒相关肝硬化后肝细胞癌复发的病例对照研究
Eur J Gastroenterol Hepatol. 2018 Apr;30(4):368-375. doi: 10.1097/MEG.0000000000001082.
2
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.2015 年全球疾病负担研究：1990 年至 2015 年全球、区域和国家一级原发性肝癌及相关病因负担。
JAMA Oncol. 2017 Dec 1;3(12):1683-1691. doi: 10.1001/jamaoncol.2017.3055.
3
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.直接作用抗病毒 HCV 治疗后肝细胞癌风险：系统评价、荟萃分析和荟萃回归。
J Hepatol. 2017 Dec;67(6):1204-1212. doi: 10.1016/j.jhep.2017.07.025. Epub 2017 Aug 9.
4
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
5
Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy.接受无干扰素治疗的丙型肝炎病毒相关肝细胞癌患者出现意外的早期肿瘤复发：肝癌治疗与抗病毒治疗之间的间隔问题。
J Hepatol. 2017 Feb;66(2):464. doi: 10.1016/j.jhep.2016.10.035. Epub 2016 Nov 10.
6
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon.根治性切除或消融术后的肝细胞癌复发：HCV 清除的影响不依赖于干扰素的使用。
Aliment Pharmacol Ther. 2017 Jan;45(1):160-168. doi: 10.1111/apt.13821. Epub 2016 Oct 28.
7
Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?对于先前肝癌已治愈的丙型肝炎病毒（HCV）患者，开具直接作用抗病毒药物后，肿瘤复发风险会增加吗？
J Hepatol. 2017 Jan;66(1):236-237. doi: 10.1016/j.jhep.2016.08.016. Epub 2016 Aug 31.
8
The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma.直接抗病毒药物对丙型肝炎相关肝细胞癌射频消融术后早期肿瘤复发的影响。
J Hepatol. 2016 Dec;65(6):1272-1273. doi: 10.1016/j.jhep.2016.07.043. Epub 2016 Aug 11.
9
High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis.丙型肝炎相关肝硬化无干扰素抗病毒治疗成功后肝细胞癌的高发病率
J Hepatol. 2016 Nov;65(5):1070-1071. doi: 10.1016/j.jhep.2016.07.027. Epub 2016 Jul 29.
10
Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.丙型肝炎相关肝细胞癌肝移植术后的直接抗病毒治疗与肿瘤复发
J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.